Cytokine Release Syndrome Epidemiology Forecast by DelveInsight

Cytokine Release Syndrome Epidemiology Forecast by DelveInsight

DelveInsight has launched a new report onCytokine Release Syndrome Epidemiology


Cytokine release syndrome (CRS) is a systemic inflammatory response with outpouring of the inflammatory cytokines due to stimulus triggered by a variety of factors such as infections, immunotherapy, especially those involving T-cell engagers and certain other drugs. Even though cytokines acts to direct immune response, the higher levels of cytokines with increased inflammation can be harmful as they interfere with a number of body functions. In severe cases, CRS can cause organ failure in heart, lung, kidney, liver, and brain function that may even lead to death.


Request for free sample copy


Cytokine Release Syndrome  Epidemiology historical as well as forecasted epidemiology in 7MM, covering the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017–2030


Cytokine Release Syndrome Epidemiology

The incidence of CRS in patients receiving cancer immunotherapy varies widely depending on the type of immunotherapeutic agent. The onset of CRS can occur within a few days, and in the case of CAR T cell therapy, up to several weeks after infusion of the drug. With most conventional monoclonal antibodies, the incidence of CRS is relatively low, whereas T cell-engaging cancer immunotherapies carry a particularly high risk of CRS.


Cytokine Release Syndrome key facts

  • Various studies estimated CRS in several hematologic malignancies, such as acute lymphoblastic B cell leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and diffuse large B cell lymphoma (DLBCL) and myeloma with an estimated range of 70%, 80%, 90% and 50% respectively.
  • In pediatric patients with ALL, the incidence of CRS following infusion of CD19-targeted CAR T cells was 100% and 76% in two clinical trials testing distinct 19-targeted CAR constructs. The causes of the higher incidence of CRS in pediatric patients are unknown but may be related to higher cell dose used or the more immature immune system of children.
  • The reported incidence of CRS after CAR T-cell therapy ranges from 50% to 100%, with 13% to 48% of patients experiencing the severe or life-threatening form.


Cytokine Release Syndrome Epidemiology Segmentation

  • Incident cases of Hematologic malignancies in 7MM [2017–2030]
  • Incident cases of Severe Cytokine Release Syndrome (CRS) in 7MM [2017–2030]
  • Incident cases of Cytokine Release Syndrome (CRS) in 7MM [2017–2030]
  • Age-specific cases of Cytokine Release Syndrome (CRS) [2017–2030]


Cytokine Release Syndrome Epidemiology Report

  • The report covers the descriptive overview of Cytokine Release Syndrome (CRS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Cytokine Release Syndrome (CRS).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Number of B-cell NHL Patients receiving CART-Therapies, Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CART-Therapies, Total Number of Multiple Myeloma (MM) Patients receiving CART-Therapies, Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies, and Total Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade.


Request for free sample copy


Table of content

1. Key Insights

2. Executive Summary of Cytokine Release Syndrome (CRS)

3. Disease Background and Overview: Cytokine Release Syndrome (CRS)

4. Case Reports

5. Epidemiology and Patient Population

6. United States Epidemiology

7. EU5 Epidemiology

8. Japan Epidemiology

9. Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight


Reasons to buy

The Cytokine Release Syndrome report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the 7MM Cytokine Release Syndrome (CRS) epidemiology forecast.
  • The Cytokine Release Syndrome (CRS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Cytokine Release Syndrome (CRS) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Related Reports


Check our latest blogs– DelveInsight Blog

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States